World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
66724
World Ranking
17775
National Ranking
8869

Overview

Rene Gonzalez is affiliated with the University of Colorado Anschutz Medical Campus in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a concentration on Oncology and Molecular Biology as key subfields.

The scientist's work focuses on several core topics, including:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Melanoma and MAPK Pathways
  • Cutaneous Melanoma Detection and Management
  • Monoclonal and Polyclonal Antibodies Research
  • Immunotherapy and Immune Responses
  • Radiopharmaceutical Chemistry and Applications

Rene Gonzalez has contributed to multiple papers published in prominent venues. Recent publications include:

  • Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma, 2022, Zurich Open Repository and Archive (University of Zurich)
  • Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629), 2020, Journal of Clinical Oncology
  • Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity, 2020, Nature Communications
  • CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma., 2021, Journal of Clinical Oncology
  • Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy, 2020, Cancers

The scientist frequently publishes in journals such as:

  • Journal of Clinical Oncology
  • Molecular Pharmaceutics
  • Cancers
  • Annals of Surgical Oncology
  • Bioconjugate Chemistry

Collaborations are a notable part of Gonzalez's work. Frequent co-authors include:

  • Karl D. Lewis
  • Theresa Medina
  • William A. Robinson
  • Jingli Xu
  • Yubin Miao

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

    Frank Stephen Hodi;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

    Fei Su;Amaya Viros;Carla Milagre;Kerstin Trunzer

  • gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

    Douglas J. Schwartzentruber;David H. Lawson;Jon M. Richards;Robert M. Conry

  • Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

    Axel Hauschild;Sanjiv S. Agarwala;Uwe Trefzer;David Hogg

  • Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

    Neil N. Senzer;Howard L. Kaufman;Thomas Amatruda;Mike Nemunaitis

  • Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

    F. Stephen Hodi;Christopher L. Corless;Anita Giobbie-Hurder;Jonathan A. Fletcher

  • Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

    Gerald S Falchook;Karl D Lewis;Jeffrey R Infante;Michael S Gordon

  • Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

    Kevin B. Kim;Richard Kefford;Anna C. Pavlick;Jeffrey R. Infante

  • Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.

    Dirk Schadendorf;Jedd D. Wolchok;F. Stephen Hodi;Vanna Chiarion-Sileni

  • Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

    Kerstin Trunzer;Anna C. Pavlick;Lynn Schuchter;Rene Gonzalez

  • Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Jean-Jacques Grob

  • Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study

    Antoni Ribas;Rene Gonzalez;Anna Pavlick;Omid Hamid

Frequent Co-Authors

Adil Daud
Adil Daud University of California, San Francisco
Steven J. O'Day
Steven J. O'Day St. John's University
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Igor Puzanov
Igor Puzanov Roswell Park Cancer Institute
Martin D. McCarter
Martin D. McCarter University of Colorado Anschutz Medical Campus
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre
F. Stephen Hodi
F. Stephen Hodi Harvard University
Keith T. Flaherty
Keith T. Flaherty Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering a career in medicine, there are flexible and affordable alternative pathways available online. Nursing programs, in particular, offer a broad range of options suited for those who want to enter healthcare or advance their qualifications without attending traditional classes.

Those looking for entry-level opportunities may want to research how much is online nursing school, as costs can vary between programs. If you are already an RN, the cheapest online BSN programs can help you earn your bachelor's degree while balancing work and family commitments.

For nursing professionals aiming for advanced roles, there are specialized online degrees such as the cheapest np school online and a range of online nursing phd programs. These programs can help you become a nurse practitioner or advance your research and teaching career.

Exploring these online degree options allows you to build a rewarding career in healthcare with greater flexibility and, often, more affordable tuition than traditional on-campus programs.

Best Scientists Citing Rene Gonzalez

Trending Scientists